SafetyTector™ S Cat. No. #400 902 ONLY for OEM
SafetyTector™ S is a SARS-CoV-2 inactivating extraction and dilution buffer for saliva specimens and nasopharyngeal swabs. Swabs can be extracted directly with SafetyTector™ S.
SafetyTector™ S eliminates the high risk of infection during and after testing coming from the specimen or other test materials. Virus inactivation was confirmed and tested with infectious viruses in a Biosafety Level 3 laboratory.
SafetyTector™ S completely eliminates infectivity of SARS-CoV-2
Samples diluted in SafetyTector™ S can directly be used in lateral flow assays and also in other immunoassays such as ELISA, protein arrays oder bead-based assays.
In tests with commercially available SARS-CoV-2 antigen rapid tests, SafetyTector™ S shows comparable or better performance than supplied extraction and dilution buffers. In some cases, further improvement in the detection limit was observed.
The suitability of SafetyTector™ S for the respective assay has to be tested by the manufacturer or distributor.
Safe Design of in vitro diagnostic medical devices (IVD products) is an obligatory pre-requisite for placing them on the international markets in the EU. This is defined in EU legislation (Directive 98/79/EG, Annex I, chapter B, clause 2.1 and Regulation (EU) 2017/746, Annex I, Chapter I, clause 4). Besides that, the ISO 14971 „application of risk management to medical devices“ (ISO 14971:2012, Annex A, chapter A.2.6 risk control) - decisive for the correct implementation of the ISO 13485 - mandates a risk control procedure and thus gives another regulatory binding basis for ensuring that IVDs are safe and secure for the user in all international markets. Safe Design includes that the risk of infection for the user is eliminated or reduced to the lowest possible level – this is especially important for IVDs for highly infectious viruses such as SARS-CoV-2. The current pandemic situation with the highly infectious variants of SARS-CoV-2 forces immediate action even for IVD products already on the market.
Virus-inactivating extraction buffers are an easy-to-use and effective tool to produce IVDs in conformity with these mandatory regulations.
During the past there were no virus-inactivating extraction buffers, proven to be able to inactivate SARS-CoV-2 by experiments under real conditions with infective viruses, available on the market.
Together with SafetyTector™ S, manufacturers of IVD directly get the necessary evidence for virus inactivation in form of a “Letter of Acknowledgement” from the testing Biosafety Level 3 laboratory.
Download Product Resources
Product Flyers and Application Guides
BIOAXXESS CANDOR Blocker Selection Guide NEW
BIOAXXESS CANDOR Product Application Guide
CANDOR Products Brochure
Assay Defender® Flyer NEW
Assay Defender® Use NEW
Assay Defender® LowCross-Buffer® Comparison Matrix NEW
SafetyTector™ S NEW
Product Inserts and Data Sheets
Assay Defender® NEW
LowCross-Buffer® Mild Animal-free/Protein-free
LowCross-Buffer® Strong Animal-free/Protein-free
LowCross® HRP-Stab Animal-free/Protein-free
LowCross® HRP-Stab Mild Animal-free/Protein-free
LowCross® HRP-Stab Strong Animal-free/Protein-free
Sample Buffer Animal-free/Protein-free
Sample Buffer IHC
Covid-19 Inactivation and Dilution Buffer
SafetyTector™ S NEW
Antibody Stabilizer TRIS
Antibody Stabilizer TRIS Animal-free/Protein-free
Antibody Stabilizer PBS
Antibody Stabilizer PBS Animal-free/Protein-free
Liquid Plate Sealer®
Liquid Plate Sealer® Animal-free
HRP-Protector™ TRIS Animal-free/Protein-free
HRP-Protector™ PBS Animal-free/Protein-free
Standard Buffers (ready-made)
Coating Buffer pH 7.4
Coating Buffer pH 9.6
Washing Buffer ReadyTector®
Washing Buffer TRIS
Washing Buffer TRIS IHC
Washing Buffer PBS
Washing Buffer PBS IHC
Interference and HAMA problems
IVD Technology Article
Long-term stabilization of assay components
Optimisation of assays: Interference in immunoassays recognize and avoid
SARS-CoV-2 antigen tests: safety for less than 5 cents per test
Specificity, positive predictive value and validation statistics in the context of CoViD-19
The Appropriate Blocker — A Short Overview
The right strategy saves much costs